GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sci Pharmtech Inc (TPE:4119) » Definitions » EV-to-EBITDA

Sci Pharmtech (TPE:4119) EV-to-EBITDA : 21.52 (As of May. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Sci Pharmtech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sci Pharmtech's enterprise value is NT$11,018 Mil. Sci Pharmtech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was NT$512 Mil. Therefore, Sci Pharmtech's EV-to-EBITDA for today is 21.52.

The historical rank and industry rank for Sci Pharmtech's EV-to-EBITDA or its related term are showing as below:

TPE:4119' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.64   Med: 11.21   Max: 162.62
Current: 21.52

During the past 13 years, the highest EV-to-EBITDA of Sci Pharmtech was 162.62. The lowest was -40.64. And the median was 11.21.

TPE:4119's EV-to-EBITDA is ranked worse than
69.93% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.42 vs TPE:4119: 21.52

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Sci Pharmtech's stock price is NT$91.90. Sci Pharmtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$2.286. Therefore, Sci Pharmtech's PE Ratio for today is 40.20.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sci Pharmtech EV-to-EBITDA Historical Data

The historical data trend for Sci Pharmtech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sci Pharmtech EV-to-EBITDA Chart

Sci Pharmtech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.02 10.27 56.64 19.98 22.45

Sci Pharmtech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.03 19.26 18.04 22.45 20.66

Competitive Comparison of Sci Pharmtech's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sci Pharmtech's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sci Pharmtech's EV-to-EBITDA falls into.



Sci Pharmtech EV-to-EBITDA Calculation

Sci Pharmtech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11018.322/511.977
=21.52

Sci Pharmtech's current Enterprise Value is NT$11,018 Mil.
Sci Pharmtech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$512 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sci Pharmtech  (TPE:4119) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sci Pharmtech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=91.90/2.286
=40.20

Sci Pharmtech's share price for today is NT$91.90.
Sci Pharmtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.286.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sci Pharmtech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sci Pharmtech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sci Pharmtech (TPE:4119) Business Description

Traded in Other Exchanges
N/A
Address
No.61, Lane 309, Haihu North Road, Luzhu District, Taoyuan, TWN, 33856
Sci Pharmtech Inc is engaged in research and development, manufacture and sale of active pharmaceutical ingredients, intermediates, specialty chemicals. Geographically, the primary markets of company are Italy, Germany, Japan, Taiwan, United states, China, Switzerland, Spain and others.

Sci Pharmtech (TPE:4119) Headlines

No Headlines